Navigation Links
PLX in Medical News

Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors

... CARMIEL, Israel, Feb. 12 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), announced today that Professor Roger D. Kornberg, renowned Biochemist and laureate of the Nobel Prize in Chemistry, has been appointed to the Compa...

Protalix BioTherapeutics Announces Resignation of Board Members

... CARMIEL, Israel, Dec. 5 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), announced today that two of its directors, Phillip Frost, M.D. and Jane H. Hsiao, Ph.D., have resigned from the Company's Board of Directors, effec...

Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific

... CARMIEL, Israel, Dec. 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), noted today that prGCD, the Company's proprietary recombinant form of Glucocerebrosidase (GCD), which is used as an enzyme replacement therapy for ...

Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment

... CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (Amex: plx ) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russ...
PLX in Medical Technology

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that Pluristem's PLacenta eXpanded (PLX) cel...

Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study

... CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that it has achieved proof of concept results in an animal study conducted as part of its Acetylcholinesterase (AChE) Program. The ...

Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

...ent treated in trial of prGCD treatment of Gaucher Disease CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate, prGCD, a proprietary...

Pluristem to Present Two Scientific Posters at the International Society for Cellular Therapy

...ccessfully show how innovative our Placenta eXpanded (PLX) cells are. These plx cells are mesenchymal stem cells expanded in our proprietary 3D PluriX(TM) ...xogenous materials. Pluristem believes the resultant expanded cells, termed plx cells, are multipotent and able to differentiate into a variety of cell typ...
PLX in Biological Technology

Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel

... CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in t...

Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders

... CARMIEL, Israel, Nov. 29 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that its board of directors has set the close of business on December 24, 2007, as the record date for shareholders entitled to rec...

Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference

... CARMIEL, Israel, Nov. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that Dr. David Aviezer, Ph.D., its President and Chief Executive Officer, will present at the CIBC World Markets 18th Annual Health...

Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock

... CARMIEL, Israel, Oct. 24 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per sha...

Protalix BioTherapeutics Announces Public Offering of Common Stock

... CARMIEL, Israel, Oct. 7 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that it has commenced a proposed underwritten public offering of its common stock pursuant to a preliminary prospectus supplement t...

Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference

... CARMIEL, Israel, Sept. 19 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: plx ), today announced that Dr. David Aviezer, its President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference at the G...

EraGen cystic fibrosis test to be distributed worldwide through Bayer

...d, then quickly developed and deployed to detect contagions such as SARS. The company offers two patented platform technologies based on AEGIS, the plx and MultiCode RTx, which the company used recently to develop a test for SARS in the U.S., just seven days after the public release of the SARS geneti...
Other Tags
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... 2014 The leading review website, ... ) and GreenGeeks are the best Dedicated Server ... those who want to buy high quality hosting ... The IT manager of Top10BestSEOHosting.com says, “We believe ... suppliers for everyone. A lot of the global ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
(Date:10/14/2014)... DURHAM, N.C. – Like discriminating thieves, prostate cancer tumors ... in the body. But such avarice may be a ... found a way to kill prostate cancer cells by ... that selectively destroys the diseased cells brimming with the ... which uses two drugs already commercially available for other ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... A team of scientists led by researchers at ... the University of Miami Miller School of Medicine ... genetic pathway underlying bipolar (manic depressive) disorder, a ... treating bipolar affective disorder, as well as depression ... findings, published online this week in Nature ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
Other Contents